Satellos Bioscience (MSCLF) Price & Analysis

Compare

24 Followers

MSCLF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.33 - $0.94

Previous CloseN/A

Volume2.00K

Average Volume (3M)29.25K

Market Cap

$75.30M

Enterprise Value$66.00M

Total Cash (Recent Filing)$41.19M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Nov 19, 2025

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding176,305,360

10 Day Avg. Volume24,503

30 Day Avg. Volume29,249

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.88

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-14.88K

Enterprise Value/Ebitda-2.39

Forecast

1Y Price Target

$0.90

Price Target Upside125.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe company has made significant progress, well positioning itself for the next value inflection point.

Drug SafetyPhase 1a data demonstrated that SAT-3247 was safe and well-tolerated across multiple dosage levels.

Bears Say

Financial PerformanceThe company reported no revenue, in line with the consensus estimate, and a net loss.

Satellos Bioscience News

Satellos Bioscience Announces Positive Phase 1b Results and Upcoming Clinical Trials for DMD

Satellos Bioscience ( ($TSE:MSCL) ) has provided an announcement. Satellos Bioscience reported positive results from its Phase 1b...

7d ago

Satellos Bioscience to Present at Canaccord Genuity’s Growth Conference

Satellos Bioscience ( ($TSE:MSCL) ) has issued an update. Satellos Bioscience Inc. announced its participation in the Canaccord...

15d ago

Satellos Bioscience to Present at Canaccord Genuity’s Growth Conference

An announcement from Satellos Bioscience ( ($TSE:MSCL) ) is now available. Satellos Bioscience Inc. announced its participation in...

15d ago

Satellos Bioscience Appoints Dr. Wildon Farwell as Chief Medical Officer to Advance Neuromuscular Therapies

Satellos Bioscience ( ($TSE:MSCL) ) just unveiled an announcement. Satellos Bioscience Inc. has appointed Dr. Wildon Farwell as...

1M ago

Satellos Bioscience Reports Shareholder Meeting Outcomes and Strategic Approvals

An update from Satellos Bioscience ( ($TSE:MSCL) ) is now available. Satellos Bioscience announced the results of its...

2M ago

Satellos Bioscience to Engage with Duchenne Community at PPMD Conference

Satellos Bioscience ( ($TSE:MSCL) ) has shared an announcement. Satellos Bioscience announced its participation in the 2025 Parent...

2M ago

Satellos Bioscience Reports Promising Phase 1b Trial Results for DMD Treatment

Satellos Bioscience ( ($TSE:MSCL) ) has issued an update. Satellos Bioscience has announced promising results from its Phase...

3M ago

Satellos Bioscience Advances DMD Drug Trials with Positive Financial Outlook

Satellos Bioscience ( ($TSE:MSCL) ) just unveiled an announcement. Satellos Bioscience has completed enrollment for its Phase 1b...

3M ago

Satellos Bioscience to Present at CureDuchenne FUTURES Conference

Satellos Bioscience ( ($TSE:MSCL) ) has shared an announcement. Satellos Bioscience Inc. announced its participation in the CureDuchenne...

4M ago

Satellos Bioscience to Present at Healthcare Investor Conference

An announcement from Satellos Bioscience ( ($TSE:MSCL) ) is now available. Satellos Bioscience Inc. announced its participation in...

4M ago

Satellos Bioscience price target raised to C$1.25 from C$1 at Canaccord

Canaccord raised the firm’s price target on Satellos Bioscience (MSCLF) to C$1.25 from C$1 and keeps a Speculative...

8M ago

Satellos Bioscience initiated with a Speculative Buy at Canaccord

Canaccord analyst Tania Armstrong-Whitworth initiated coverage of Satellos Bioscience with a Speculative Buy rating and C$1 price target....

11M ago

Satellos Bioscience submits clinical research proposal to HREC for SAT-3247

Satellos Bioscience announced submission of a clinical research proposal to a Human Research Ethics Committee, or HREC, in...

1y ago

Satellos Bioscience granted orphan status for DMD treatment

The FDA granted Satellos Bioscience orphan status for its treatment of Duchene muscular dystrophy. Published first on TheFly...

1y ago

MSCLF FAQ

What was Satellos Bioscience’s price range in the past 12 months?

Satellos Bioscience lowest stock price was $0.33 and its highest was $0.94 in the past 12 months.

What is Satellos Bioscience’s market cap?

Satellos Bioscience’s market cap is $75.30M.

When is Satellos Bioscience’s upcoming earnings report date?

Satellos Bioscience’s upcoming earnings report date is Nov 19, 2025 which is in 91 days.

How were Satellos Bioscience’s earnings last quarter?

Satellos Bioscience released its earnings results on Aug 13, 2025. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.022 by -$0.008.

Is Satellos Bioscience overvalued?

According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience pay dividends?

Satellos Bioscience does not currently pay dividends.

What is Satellos Bioscience’s EPS estimate?

Satellos Bioscience’s EPS estimate is -0.01.

How many shares outstanding does Satellos Bioscience have?

Satellos Bioscience has 176,305,360 shares outstanding.

What happened to Satellos Bioscience’s price movement after its last earnings report?

Satellos Bioscience reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.022. Following the earnings report the stock price went down -6.818%.

Which hedge fund is a major shareholder of Satellos Bioscience?

Currently, no hedge funds are holding shares in MSCLF

Satellos Bioscience Stock Smart Score

Underperform

Fundamentals

Return on Equity

-76.26%

Trailing 12-Months

Asset Growth

69.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Satellos Bioscience (MSCLF) Earnings & Revenues

Historic Earnings Reports

MSCLF Stock 12 Month Forecast

Average Price Target

$0.90

▲(125.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.90482,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.90482,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.4942169230769231,0.5284338461538461,0.5626507692307693,0.5968676923076923,0.6310846153846155,0.6653015384615385,0.6995184615384615,0.7337353846153847,0.7679523076923077,0.8021692307692307,0.8363861538461539,0.8706030769230769,{"y":0.90482,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.4938461538461539,0.5276923076923077,0.5615384615384615,0.5953846153846154,0.6292307692307693,0.6630769230769231,0.696923076923077,0.7307692307692308,0.7646153846153847,0.7984615384615386,0.8323076923076923,0.8661538461538462,{"y":0.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.4942169230769231,0.5284338461538461,0.5626507692307693,0.5968676923076923,0.6310846153846155,0.6653015384615385,0.6995184615384615,0.7337353846153847,0.7679523076923077,0.8021692307692307,0.8363861538461539,0.8706030769230769,{"y":0.90482,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.51,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.44,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.44,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >